Scholarship program helps people living with epilepsy, family members
and caregivers pursue academic and personal development opportunities
related to their experiences with epilepsy
DEERFIELD, Ill.–(BUSINESS WIRE)–Citizens United for Research in Epilepsy (CURE) and Lundbeck today
announced the launch of the CURE Education Enrichment Fund Scholarship
Program, which is a one-time scholarship (up to $5,000) for people who
are living with epilepsy, family members and caregivers. These
scholarships will help advance the recipients’ personal knowledge in
research, health education, advocacy and/or awareness as it relates to
their experiences with epilepsy.
“We have met so many amazing people in the epilepsy community who have a
strong desire to make a difference in the lives of others who are
struggling with this condition, and just need a little extra support to
help make their ambitions a reality,” said Lorena Di Carlo, Vice
President & General Manager, Neurology, at Lundbeck. “The Education
Enrichment Fund will give people that much-needed support. This program
expands upon Lundbeck’s long-standing commitment to the epilepsy
community and dedication to empowering people who are living with
epilepsy and their caregivers.”
“The Education Enrichment Fund was partly inspired by CURE’s associate
research director, Dr. Tracy Dixon Salazar, a stay-at-home mom
determined to help her daughter who had been diagnosed with
Lennox-Gastaut syndrome, a severe form of epilepsy,” said Robin Harding,
Chief Executive Officer of CURE. “She began reading journal articles
about the disease, studying biology, and soon returned to school,
spending the next 15 years furthering her education. Dr. Salazar, now a
Ph.D. in neuroscience and an epilepsy genetics researcher, has turned
this passion into her life’s work, applying her knowledge to care for
her daughter and empowering the epilepsy community through CURE. Hers is
just one story of the power of knowledge and we are so thankful to
Lundbeck for sponsoring this new program. We look forward to seeing the
impact on patients’ lives that will come of it.”
CURE awarded three scholarships through the Education Enrichment Fund
pilot program earlier this year. While all applicants had truly
inspirational stories and compelling reasons for wanting to further
their education, three applications really stood out:
A mother who struggled with not knowing the answer to her child’s
epilepsy, but never gave up. After finally identifying a genetic
cause, she helped form a non-profit foundation that provides support
to other families who have had this same diagnosis. She plans to use
her scholarship to learn how to effectively write grants and raise
funds for research, while also learning best practices to advocate in
the healthcare and political arenas.
A sister who watched her little brother battle seizures daily and
struggled to find a way to help him improve his quality of life. She
realized that as a sibling of someone whose seizures dictated his
entire life, it seemed appropriate that she devote hers to helping
children, like her brother, who have been living with severe
disabilities. She will be using her scholarship toward her recent
acceptance into a nationally ranked Masters of Education program,
where she will focus on educating children with severe disabilities.
A young woman who developed epilepsy later in life, and fought the
misconceptions and discrimination that surrounds people living with
epilepsy every day. She is currently pursuing her Master’s in Public
Health where she plans to use her scholarship to help her effectively
advocate for her community and create policies to help improve the
quality of life of people, just like her, who struggle with epilepsy
and other chronic conditions.
CURE is now accepting applications for the Education Enrichment Fund.
The deadline to submit applications is April 15, 2017. To learn more
about the scholarship program and to apply, visit www.CUREepilepsy.org.
Lundbeck is a global pharmaceutical company specialized in psychiatric
and neurological disorders. For more than 70 years, we have been at the
forefront of research within neuroscience. Our key areas of research
focus are depression, schizophrenia, Parkinson’s disease and Alzheimer’s
An estimated 700 million people worldwide are living with psychiatric
and neurological disorders and far too many suffer due to inadequate
treatment, discrimination, a reduced number of working days, early
retirement and other unnecessary consequences. Every day, we strive for
improved treatment and a better life for people living with psychiatric
and neurological disorders — we call this Progress in Mind.
Our approximately 5,000 employees in 55 countries are engaged in the
entire value chain throughout research, development, manufacturing,
marketing and sales. Our pipeline consists of several late-stage
development programs and our products are available in more than 100
countries. We have research centers in China and Denmark and production
facilities in China, Denmark, France and Italy. Lundbeck generated core
revenue of DKK 14.6 billion in 2015 (EUR 2 billion; USD 2.2 billion).
In the U.S., Lundbeck employs nearly 1,000 people focused solely on
accelerating therapies for brain disorders, including epilepsy. With a
special commitment to the lives of patients, families and caregivers,
Lundbeck U.S. actively engages in hundreds of initiatives each year that
support our patient communities.
For additional information, visit www.lundbeckus.com
and connect on Twitter at @LundbeckUS.
Citizens United for Research in Epilepsy (CURE)
is the leading nongovernmental agency fully committed to funding
research in epilepsy. The organization was founded by Susan
Axelrod and a small group of parents of children with epilepsy who
were frustrated with their inability to protect their children from
seizures and the side effects of medications. Unwilling to sit back,
they joined forces to spearhead the search for a cure.
Since its inception in 1998, CURE has been at the forefront of epilepsy
research, raising more than $40 million to fund research
and other initiatives that will lead the way to a cure for epilepsy.
CURE funds grants for emerging and established investigators, and to
date has awarded more than 200 cutting-edge projects in 15 countries
around the world.
CURE has led a dramatic shift in the epilepsy research community
from simply treating seizures to enhancing understanding of underlying
mechanisms and causes, so that cures and preventative strategies can be
found. CURE’s research program is cutting-edge, dynamic and responsive
to new scientific opportunities and directions through both
investigator-initiated grants and unprecedented scientific programs and
CURE’s mission is to cure epilepsy, transforming and saving
millions of lives. We identify and fund cutting-edge research,
challenging scientists worldwide to collaborate and innovate in pursuit
of this goal. Our commitment is unrelenting.